# An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children

> **NCT00791700** · PHASE2 · UNKNOWN · sponsor: **ViiV Healthcare** · enrollment: 103 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Maraviroc

## Key facts

- **NCT ID:** NCT00791700
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-04-22
- **Primary completion:** 2015-04-14
- **Final completion:** 2023-06-30
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2020-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791700

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791700, "An Open Label Pharmacokinetic, Safety And Efficacy Study Of Maraviroc In Combination With Background Therapy For The Treatment Of HIV-1 Infected, CCR5 -Tropic Children". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00791700. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*